top of page

Return of the drug developer

  • 2 hours ago
  • 1 min read

The biotechnology sector is showing renewed signs of life, with improving funding conditions, increased M&A activity and a stronger focus on companies advancing high-quality clinical programs. As sentiment shifts back towards innovation and execution, the next generation of drug developers could present compelling opportunities for long-term investors.


"Taking on a challenge is a lot like riding a horse; if you're comfortable while you're doing it, you're probably doing it wrong." — Ted Lasso

 

In this latest article, Portfolio Manager Anthony Kavanagh explores why the environment for drug developers is improving, what is driving renewed investor interest, and the characteristics they believe separate the most promising companies from the rest.


Click here to read the full article on Livewire.

Click here to download the PDF version.

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.

Melbourne (Head Office) 

Level 47, 80 Collins Street (North Tower)
Melbourne VIC 3000

​

Sydney
Governor Macquarie Tower
Level 25, 1 Farrer Place,

Sydney NSW 2000

​

Brisbane

Suite 24, Level 18, 324 Queen Street, Brisbane QLD 4000

​

DISCLAIMER

 

This website provides information to help investors and their advisers assess the merits of investing in financial products. We strongly advise investors and their advisers to read information memoranda and product disclosure statements carefully.

​

The information on this website does not constitute personal advice and does not take into account your investment objectives, financial situation or needs. It is therefore important that if you are considering investing in any financial products and services referred to on this website, you determine whether the relevant investment is suitable for your needs, objectives and financial circumstances. You should also consider seeking independent financial advice, particularly on taxation, retirement planning and investment risk tolerance before making an investment decision.

​

Neither Copia Investment Partners Limited, nor any of our associates, guarantee or underwrite the success of any investments, the achievement of investment objectives, the repayment of capital or payment of particular rates of return on investments.

​

Copia Investment Partners Limited publishes information on the website that to the best of its knowledge is current at the time and is not liable for any direct or indirect losses attributable to omissions from the website, information being out of date, inaccurate, incomplete or deficient in any other way. Investors and their advisers should make their own enquiries before making investment decisions.

​​

© 2026 Copia Investment Partners Limited

bottom of page